Molecular Determinants of Sotorasib Efficacy in Patients with Advanced KRASG12C-mutated NSCLC By Ogkologos - June 6, 2025 622 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from integrated analyses of sotorasib clinical efficacy biomarkers in the CodeBreaK 100 and CodeBreaK 200 studies Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR Courageous children receive Star Awards in virtual celebration December 17, 2021 What is De-escalation Treatment in Cancer Research? May 30, 2023 Study Tackles Key Questions about Liver Transplants for People with Liver... August 24, 2022 Health inequalities: “We have a moral duty to reduce them” February 15, 2022 Load more HOT NEWS Virtual Reality Found to Benefit Cancer Patients’ Mental Health What the Reignited Cancer Moonshot Initiative Means for People With Cancer FDA Approves Tisotumab Vedotin-tftv for Recurrent or Metastatic Cervical Cancer Identifying Safer Ways to Look for Recurrence After Testicular Cancer Surgery
